Stereotactic Body Radiotherapy for Early Stage Breast Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.
Who Is on the Research Team?
D. Hunter Boggs, MD
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for women over 50 with early stage breast cancer who've had a lumpectomy. They must have ER-positive tumors smaller than 2cm (or 2.5cm if it's DCIS), no cancer in the lymph nodes, and be generally healthy. Women can't join if they have invasive lobular cancer, unclear lumpectomy margins on scans, received chemo before surgery, or have multifocal/multicentric cancer.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 5 fractions of stereotactic body radiotherapy for early stage breast cancer after lumpectomy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 1-3 Fraction Stereotactic Body Radiation Therapy
- 5 Fraction Stereotactic Body Radiation Therapy
- Single Fraction Stereotactic Body Radiation Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
Varian Medical Systems
Industry Sponsor
Dow R. Wilson
Varian Medical Systems
Chief Executive Officer since 2012
MBA from Dartmouth's Amos Tuck School of Business, BA from Brigham Young University
Dr. Deepak Khuntia
Varian Medical Systems
Chief Medical Officer since 2020
MD from the University of Cambridge, PhD from the University of Leicester